Viking Therapeutics Inc

VKTX

Equity

ISIN null / Valor 24839858

NASDAQ (2025-10-20)

USD 33.75+0.64%

Viking Therapeutics Inc
UMushroom community rating:

4.63 2 votes No rating yet

NegativeNeutralPositive

About company

Viking Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders.

Summarized from source with an LLMView SourceSector: Healthcare

R&D Expenses Soar

Research and development expenses surged to $60.2 million for the three months ended June 30, 2025, up from $23.8 million in the second quarter of 2024. This increase was primarily driven by higher costs associated with clinical studies, drug manufacturing, pre-clinical research, stock-based compensation, and enhanced salaries and benefits.

General & Administrative Costs Rise

General and administrative expenses increased to $14.4 million for the same period, compared to $10.3 million in the second quarter of 2024. The rise in G&A expenses was mainly due to higher stock-based compensation and salaries, partially offset by reduced spending on legal and patent services.

Net Loss Increases

For the three months ended June 30, 2025, Viking reported a net loss of $65.6 million, or $0.58 per share, compared to a net loss of $22.3 million in the second quarter of 2024. The expanded investment in research and development and administrative functions contributed to the higher net loss.

Robust Cash Position Maintained

The company closed the second quarter with a strong cash position of $808 million, providing ample runway to support the advancement of VK2735 through Phase 3 clinical trials and to further develop other key programs.

Summarized from source with an LLMView Source

Key figures

-48.7%1Y

800%3Y

506%5Y

Performance

93.2%1Y

105%3Y

89.1%5Y

Volatility